BeOne Medicines (ONC) EBT (2015 - 2026)

BeOne Medicines (ONC) has 12 years of EBT data on file, last reported at $259.2 million in Q1 2026.

• On a quarterly basis, EBT rose 1140.26% year-over-year to $259.2 million in Q1 2026; TTM through Mar 2026 was $655.2 million, a 343.85% increase from a year earlier, with the FY2025 full-year figure at $416.9 million, up 178.21% from the prior year.
• EBT for Q1 2026 stood at $259.2 million, up from $149.2 million in the prior quarter.
• Over the last five years, EBT for ONC reached as high as $259.2 million in Q1 2026 and fell as low as -$557.6 million in Q2 2022.
• Historically, EBT has averaged -$155.5 million across 5 years, with a median of -$105.9 million in 2024.
• Across the five-year window, EBT plunged 780.92% in 2022 and soared 1140.26% in 2026, its largest moves.
• Year by year, EBT stood at -$431.0 million in 2022, then grew by 18.61% to -$350.8 million in 2023, then soared by 75.67% to -$85.4 million in 2024, then jumped by 274.86% to $149.2 million in 2025, then soared by 73.69% to $259.2 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $259.2 million in Q1 2026, $149.2 million in Q4 2025, and $147.2 million in Q3 2025.